Omaha、NEにおける乳がんの臨床試験
Omahaとその周辺地域（約30マイル以内）の拠点で、乳がんに関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
被験者募集中第3相
- Research Site, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- Nebraska Cancer Specialists, Omaha
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
- University of Nebraska Medical Center, Omaha
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Nebraska Medicine-Village Pointe, Omaha
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- 他3件
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
被験者募集中第1相
- Nebraska Cancer Specialists, Omaha
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
被験者募集中第3相
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Integrated Cancer Repository for Cancer Research
被験者募集中観察研究健康なボランティア歓迎
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- 他1件
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
被験者募集中第1相
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
ERAS Protocols in Breast Conserving Surgery
被験者募集中
- University of Nebraska Medical Center, Omaha
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Omaha
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
被験者募集中第1相
- Biotheryx Investigative Site, Omaha
CtDNA Based MRD Testing for NAC Monitoring in TNBC
被験者募集中観察研究
- Nebraska Methodist, Omaha
他の都市における乳がんの試験
- New York City, NY134件の研究
- Houston, TX126件の研究
- Boston, MA111件の研究
- Nashville, TN80件の研究
- Los Angeles, CA72件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Durham, NC63件の研究
- Queens, NY63件の研究
- Chicago, IL58件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Omahaにおける他の研究
- 前立腺がん27件の研究
- 非小細胞肺癌24件の研究
- 大腸癌18件の研究
- がん（全種類）18件の研究
- 多発性骨髄腫16件の研究
- 非ホジキンリンパ腫14件の研究
- 卵巣がん14件の研究
- 膵臓がん14件の研究
- 頭頸部扁平上皮癌13件の研究
- 心不全13件の研究
- 転移性癌13件の研究
- 腎臓がん（腎細胞がん）12件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。